Entering text into the input field will update the search result below

Synergy Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

SA Transcripts profile picture
SA Transcripts

The following slide deck was published by Synergy Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings call.


This article was written by

SA Transcripts profile picture
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Recommended For You

Comments (11)

Going to wish we all had more shares over the next 18-24 months
petektf profile picture
Sounds great but why is the market just flat or even down? I guess we need to see them reach more milestones first.
I thought the presentation was informative and feel my investment is good long. Not often you can ground floor in the Pharmaceutical world with good results. Once a molecule begins the FDA process, 3 phases and millions of dollars. There is little guarantee they will make it to market. Much less be a success. I have been in both worlds for many years with some success. Pharm and investing. Synergy and Trulance looks to be the most promising of them all. There have been bumps in the road and no doubt will be more for this young company. If you are looking for a quick profit, please invest elsewhere. There will be no BO, partnership for added voice, yes. 2018 will be a good year. But Synergy will not hit its stride till 2019 and beyond. Nothing is a sure thing. But this young company has a future with a true best in class drug.
Well said !! I really don’t understand why a single drug costs so much from inception through fda process and very expensive marketing ie 45m per qrtr cash burn Highly inefficient system we have in the great USA 🇺🇸!!! I agree no BO this year but No partnership ever 2019 and 2020 they will be killing it !! Long SGYP
How much do you have riding in SGYP ? I have 13,300 shares
Watching and reading the comments..
umiak profile picture
01 Mar. 2018
If they run a tight ship their ##s will improve and pps will rise
I may be looking for the silver linings. But, I am still a believer of the product and now I think Managment is doing more of the right things. I like the 2nd debt restructuring and feel that it will force them to creat more revenue opportunities with “rights” to EU and other markets. That to me might accelerate and motivate potential suitors for a sale. Thoughts?
Agree. Revs are not great at this point, but at least management seems a bit less tone deaf. Reduce Opex. Look for more deals outside US.

Maybe move the HQ out of NYC?
Philip3 profile picture
"Exploring all Financial Strategic and Business Developments Opportunities."
That's what I wanted to hear :) sell the product, raise the stock price, and then sell the company.
Percentage growth looks good, just on a small scale.
Heard a lot of good things on the call, especially with regards to getting much better insurance coverage for Trulance. But why rule out a buy-out? That can only help the company's valuation.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.